Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
VANTRELA ER is an extended-release oral tablet formulation of hydrocodone bitartrate, an opioid analgesic indicated for moderate-to-severe pain management. The drug works by binding to opioid receptors in the central nervous system to reduce pain perception. It is designed for patients requiring around-the-clock opioid therapy.
Peak lifecycle stage with high competitive pressure (score: 8/10) suggests mature market with entrenched sales infrastructure and limited expansion opportunity.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children
Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain
Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Worked on VANTRELA ER at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
VANTRELA ER offers limited career growth opportunity given zero linked job postings and peak lifecycle stage with declining exclusivity. Roles available are primarily sales, account management, and field-based positions focused on market defense rather than expansion.